Gritstone bio
Gritstone’s goal is to develop groundbreaking immunotherapies for cancers and infectious diseases. Our approach focuses on generating a therapeutic immune response in these patients by unleashing the natural power of a patient’s immune system to recognize and destroy tumors or virally infected cells.
Our Pipeline - Gritstone bio
A routine clinical biopsy can be used to identify patients that have common mutations within their tumor through commercially available genomic panel sequencing. These common driver mutations have been shown to produce shared neoantigens …
About - Gritstone bio
Gritstone bio is developing next-generation vaccines for cancer and infectious disease. Gritstone’s approach seeks to generate potent and durable immune responses by leveraging insights into the immune system’s ability to recognize and destroy diseased cells by targeting select antigens.
Nature Medicine Publishes Interim Results from ... - Gritstone bio
2024年4月15日 · Gritstone’s neoantigen-based vaccine programs, GRANITE (personalized) and SLATE (“off-the-shelf) are engineered to elicit a significant T cell response for patients with solid tumors.
Our Approach – Gritstone bio
Within our CORAL program, Gritstone is developing multiple vaccine candidates designed to deliver Spike and additional SARS-CoV-2 T cell epitopes against COVID-19 using its novel vector, self-amplifying mRNA (samRNA).
Scientific Publications - Gritstone bio
Gritstone. About Us. Our Unique Story Leadership Board of Directors. Our Platforms. Proprietary Technologies Approach to Cancer Approach to ID Treatment Approach to ID Prevention Scientific Publications. Our Pipeline. Vaccine Pipeline GRANITE SLATE HIV Therapeutic CORAL. Career Opportunities ...
Gritstone bio Announces Interim Phase 2 Data for GRANITE …
EMERYVILLE, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced encouraging interim Phase 2 data from the ongoing Phase 2 study evaluating GRANITE, its individualized neoantigen targeting immunotherapy, in ...
Gritstone bio Reports Second Quarter 2023 Financial Results and ...
2023年6月30日 · Gritstone delivered multiple presentations detailing advances in neoantigen prediction capabilities and cancer vaccine programs at the 2023 American Association for Cancer Research (AACR 2023, in April 2023).
Gritstone Announces Promotions Within its Leadership Team
EMERYVILLE, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Gritstone Oncology, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company developing the next generation of cancer and infectious disease immunotherapies, today announced two promotions within its leadership team.
Career Opportunities - Gritstone bio
Gritstone is a mission-driven organization with a goal of eradicating diseases through the development of next generation immunotherapies. We value and foster a culture of collaboration, discovery and passion. Join our team.
- 某些结果已被删除